From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

ATH-1105 is the Company's novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to ...

HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration Successful completion of the first ...

Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

New Delhi: Rejecting the proposal for the local Phase III clinical trial waiver, the Subject Expert Committee (SEC) ...

Herantis Pharma Plc - Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson's disease HER-096 is a first-in-class agent in development for ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Research shows 65% of migraine patients experience nausea. Discover 5 treatments that provide relief during attacks.

Close collaboration between researchers and clinicians at Mayo is what makes the steps of translation — from discovery to the ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application ...

Sarepta Therapeutics has announced new outcomes from its Phase Ib Study 9001-103, named Endeavour, of Elevidys for DMD.